ライフサイエンスコーパス: laboratory animal

1 body plan provide the ideal attributes for a laboratory animal.

2 reproductive and developmental toxicants in laboratory animals.

3 d longevity and improve health parameters in laboratory animals.

4 popular technique for tinnitus assessment in laboratory animals.

5 ection techniques for tinnitus assessment in laboratory animals.

6 use this disease does not occur naturally in laboratory animals.

7 sidered when imposing husbandry variables on laboratory animals.

8 memory that has been studied extensively in laboratory animals.

9 e pathophysiologic processes in patients and laboratory animals.

10 arch Council's Guide for the Care and Use of Laboratory Animals.

11 sulin-like growth factor I (IGFI) pathway in laboratory animals.

12 and reduces the growth of existing tumors in laboratory animals.

13 gainst carcinogenesis and extend lifespan in laboratory animals.

14 ectivity/cytopathology and pathogenicity for laboratory animals.

15 e and across humans, other natural hosts and laboratory animals.

16 reasingly important to assess mood states in laboratory animals.

17 uating the effects of analgesic compounds in laboratory animals.

18 ve a significant impact on a large number of laboratory animals.

19 es, which have been shown to cause cancer in laboratory animals.

20 found effects on the health and longevity of laboratory animals.

21 utes of Health standards for care and use of laboratory animals.

22 as been found to be a complete carcinogen in laboratory animals.

23 ire the gathering of pharmacokinetic data in laboratory animals.

24 have not elicited neutralizing antibodies in laboratory animals.

25 pment by streamlining preclinical testing in laboratory animals.

26 nduce primary brain cancers and lymphomas in laboratory animals.

27 man subjects, analogous to those reported in laboratory animals.

28 een relatives is well known from captive and laboratory animals.

29 a DNA tumor virus known to induce cancers in laboratory animals.

30 infect human beings and to induce tumours in laboratory animals.

31 NA vaccines administered to the epidermis of laboratory animals.

32 s also been isolated from a wide spectrum of laboratory animals.

33 presses ethanol intake in alcohol-preferring laboratory animals.

34 sed for long-term studies in immunocompetent laboratory animals.

35 known to impair motor function in humans and laboratory animals.

36 dopamine (DA) terminals when administered to laboratory animals.

37 nd progression of atherosclerotic lesions in laboratory animals.

38 DBP and a DNA vaccine were used to immunize laboratory animals.

39 ciated with cognitive deficits in humans and laboratory animals.

40 nderground miners and experimentally exposed laboratory animals.

41 presses ethanol intake in ethanol-preferring laboratory animals.

42 coprivic conditions markedly increase CBF in laboratory animals.

43 tion against a tick-transmitted infection on laboratory animals.

44 gated during insulin-induced hypoglycemia in laboratory animals.

45 f California, Los Angeles, for imaging small laboratory animals.

46 P-induced central nervous system toxicity in laboratory animals.

47 notypes and virulence in cell monolayers and laboratory animals.

48 s enterohepatic disease in many domestic and laboratory animals.

49 sely affected by alcohol abuse in humans and laboratory animals.

50 wn in the modulation of memory in humans and laboratory animals.

51 ting experimental drugs in T. cruzi-infected laboratory animals.

52 ne transporter sites in vitro and in vivo in laboratory animals.

53 many different types of injury in humans and laboratory animals.

54 ollowing the injection of patient blood into laboratory animals.

55 on, such as cognitive control, in humans and laboratory animals.

56 e span and delay age-associated pathology in laboratory animals.

57 t phenotypes across clinical populations and laboratory animals.

58 from studies of modern human populations and laboratory animals.

59 ness of the extremities in exposed human and laboratory animals.

60 xperimental data from domestic livestock and laboratory animals.

61 Service Policy on the Humane Care and Use of Laboratory Animals.

62 iting factor of hepatocytes in commonly used laboratory animals.

63 activity under well-controlled conditions in laboratory animals.

64 in ticks and tissue samples from humans and laboratory animals.

65 rcinogens, and potent mammary carcinogens in laboratory animals.

66 havior is limited by its apparent absence in laboratory animals.

67 er than ever before and to reduce testing on laboratory animals.

68 what is known from classical neuroanatomy in laboratory animals.

69 supporting cellular and molecular studies in laboratory animals.

70 ve been shown to cause neurotoxic effects in laboratory animals.

71 ut alternative to brain tissues excised from laboratory animals.

72 same endpoints can be studied in humans and laboratory animals.

73 of Health guidelines for the care and use of laboratory animals.

74 n reached in a wide variety of studies using laboratory animals.

75 iance with the Guide for the Care and Use of Laboratory Animals.

76 for consecutive PET and MR imaging of small laboratory animals.

77 Antisera raised in laboratory animals against SD3, SD3+, and SD2+3 inhibite

78 ucts progressively disappear from the DNA of laboratory animals, AL-dA lesions has lasting persistenc

79 anism of action of antidipsotropic agents in laboratory animals, aldehyde dehydrogenase (ALDH) isozym

80 Unlike laboratory animals, all humans are infected with multipl

81 We carried out the health check-up on laboratory animal allergy (LAA) by questionnaires and sp

82 ied on allergic sensitization prevalence for laboratory animals among students and researchers who ar

83 ian cue integration approach been applied to laboratory animals, an important step toward understandi

84 Laboratory animal and human evidence for these three the

85 sent review examines the available data from laboratory animal and human intervention studies on tea

86 Included were laboratory animal and human studies relevant to immune f

87 and expensive to obtain-a common problem in laboratory animal and human studies.

88 nstitutes of Health Guidelines on the Use of Laboratory Animals and approved by the Institutional Ani

89 -fetal interface and to overcome the need of laboratory animals and human embryos.

90 ion of memory, highlighting relevant work in laboratory animals and human subjects.

91 wledge of these properties for commonly used laboratory animals and humans ( 30 g to 150 kg).

92 Investigations in both laboratory animals and humans indicate that cells, organ

93 Experimental studies in laboratory animals and humans suggest that alpha-linolen

94 the extent of potential differences between laboratory animals and humans, through direct study of h

95 lso causes features of metabolic syndrome in laboratory animals and humans.

96 ion results in diaphragmatic atrophy in both laboratory animals and humans.

97 uences spatial orientation and navigation in laboratory animals and humans.

98 ibody preparations; removing the need to use laboratory animals and implementing a truly universal sy

99 an minimize a widespread source of stress in laboratory animals and improve welfare through refinemen

100 ce to organ transplants has been reported in laboratory animals and in humans after nonmyeloablative

101 evelopment cause congenital heart defects in laboratory animals and in man.

102 e differences between experimental models in laboratory animals and naturally occurring traumatic inj

103 falciparum sporozoites do not infect common laboratory animals and only develop in vitro in human he

104 otent effects of therapeutic angiogenesis in laboratory animals and the marginal results observed in

105 mental autoimmune encephalomyelitis (EAE) in laboratory animals and the presumed mediators of multipl

106 ed widely to develop human disease models in laboratory animals and to study gene functions by silenc

107 It is also a very useful laboratory animal, and readily lends itself to the trans

108 licit different effects when administered to laboratory animals, and are expressed using different re

109 n produces stress-like effects in humans and laboratory animals, and CRF levels are elevated in indiv

110 gnition, neuroprotection and neurogenesis in laboratory animals, and has entered phase II clinical tr

111 studies with germ-free or antibiotic-treated laboratory animals, and human studies that evaluated how

112 alises the effects of endotoxin in vitro, in laboratory animals, and in humans.

113 been studied at the cochlear base in various laboratory animals, and the assumption has been that the

114 Numerous studies document RNAi efficacy in laboratory animals, and the first clinical trials are un

115 Epidemiologic, laboratory, animal, and clinical studies suggest that th

116 ity of the brain of normal, awake humans and laboratory animals are accompanied almost invariably by

117 trophils, macrophages and dendritic cells in laboratory animals are discussed.

118 study the abuse-related effects of drugs in laboratory animals are intravenous drug self-administrat

119 Humans and laboratory animals are thought to discriminate sensory o

120 Among laboratory animals, AS(PV) and ex vivo results were simi

121 NNK and NNAL can induce lung cancer in laboratory animals but human data are limited.

122 othiocyanates inhibit lung carcinogenesis in laboratory animals but human data are limited.

123 at and protect against insulin resistance in laboratory animals, but it is not known whether DHEA dec

124 blood concentrations of thyroid hormones in laboratory animals, but it is unclear whether PBDEs disr

125 ics has revolutionized neuroscience in small laboratory animals, but its effect on animal models more

126 mprove the health and extend the lifespan of laboratory animals, but its effect on humans has never b

127 t stress (RS) causes analgesia in humans and laboratory animals, but the underlying mechanisms are un

128 ascular hyperplasia in immunologically naive laboratory animals, but their usefulness for intra-arter

129 ore-than-additive effects on drug seeking in laboratory animals, but, surprisingly, seem to compete w

130 se model inducible in susceptible strains of laboratory animals by immunization with protein constitu

131 tury, malignant skin tumors were produced in laboratory animals by repeatedly painting them with coal

132 are readily self-administered by humans and laboratory animals by virtue of their actions on dopamin

133 Lifespan of laboratory animals can be increased by genetic, pharmaco

134 First, studies of laboratory animals can help to distinguish between healt

135 ibum collected from humans and three typical laboratory animals, canines, mice, and rabbits, for thei

136 by the Institutional Administrative Panel on Laboratory Animal Care at Stanford University.

137 by the Institutional Administrative Panel on Laboratory Animal Care at Stanford University.

138 by the institutional administrative panel on laboratory animal care.

139 by the Institutional Administrative Panel on Laboratory Animal Care.

140 by the Institutional Administrative Panel on Laboratory Animal Care.

141 by the Institutional Administrative Panel on Laboratory Animal Care.

142 by the Institutional Administrative Panel on Laboratory Animal Care.

143 by the institutional Administrative Panel on Laboratory Animal Care.

144 were approved by the administrative panel on laboratory animal care.

145 ved by the ethical committee of the National Laboratory Animal Center.

146 In farm and laboratory animals, chronic exposure to aflatoxins compr

147 ted the suitability of nine potential RGs in laboratory animals commonly used to study viral hemorrha

148 ne release and conditioned drug responses in laboratory animals-could inhibit mesolimbic activation e

149 Laboratory animal data indicate that "activation" and "t

150 Studies in laboratory animals demonstrate important relationships b

151 for studies on CQA bioactivity, plant-based laboratory animal diets contain CQAs, which makes it dif

152 Because standard laboratory animal diets contain high levels of folic aci

153 en used as an index of defensive response in laboratory animals during Pavlovian fear conditioning.

154 Handling laboratory animals during test procedures is an importan

155 nding orbital region of prefrontal cortex in laboratory animals encode information regarding the ince

156 tocol using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) approach.

157 including p53 and pRB: The observations from laboratory animal experiments have provided a rationale

158 neurobehavioral deficits in the offspring of laboratory animals exposed to moderate levels of ethanol

159 his conclusion is supported by findings from laboratory animals exposed to nicotine during developmen

160 In laboratory animals, exposure to most general anaesthetic

161 version to infectious agents is critical for laboratory animal facility disease monitoring.

162 were healthy when maintained in the standard laboratory animal facility.

163 wide variety of immunologic interventions in laboratory animals, few tolerance induction protocols wi

164 linical signs and pathogenesis of disease in laboratory animals following HRSV infection differs from

165 ric disorders, such as schizophrenia, and in laboratory animals following specific pharmacological ma

166 nistration behavior has been demonstrated in laboratory animals for almost all other psychoactive dru

167 There is increasing evidence in humans and laboratory animals for biologically based sex difference

168 ancing Science and Elimination of the Use of Laboratory Animals for Development and Control of Vaccin

169 Studies in laboratory animals found that iron deficiency without an

170 tion of the dithiolethione oltipraz protects laboratory animals from the development of tumors follow

171 In laboratory animals, genetics and environment are variabl

172 mproving the welfare of the most widely used laboratory animal globally.

173 liant with the Guide for the Care and Use of Laboratory Animals (Guide) unless scientifically justifi

174 Routine laboratory animal handling has profound effects on their

175 f behavioral paradigms designed for nonhuman laboratory animals has also had a significant impact on

176 man adenoviruses to replicate efficiently in laboratory animals has hampered the study of such vector

177 Recent research in laboratory animals has illuminated how the vertebrate gu

178 rganisms isolated from the lungs of infected laboratory animals have been developed.

179 Although induced mutations in traditional laboratory animals have been valuable as models for huma

180 hetic ganglia neurons in the lower airway of laboratory animals have membrane properties associated w

181 r mice made in the Guide for Care and Use of Laboratory Animals have not changed since 1972, despite

182 ies using candidate therapeutic molecules in laboratory animals have provided encouraging results: sy

183 Epidemiological and model studies with laboratory animals have provided evidence that nonsteroi

184 Studies of laboratory animals have shown that administration of ant

185 idemiologic studies and research findings in laboratory animals have shown the chemopreventive potent

186 , most behavioral studies of anxiety rely on laboratory animals housed in static, impoverished condit

187 Unlike laboratory animals, humans are infected with multiple pa

188 , substantive differences between humans and laboratory animals in efficiency of iAs methylation have

189 y challenged murine macrophages in vitro and laboratory animals in vivo.

190 edition of the Guide for the Care and Use of Laboratory Animals included new recommendations for the

191 ly purified from a patient with diarrhea, in laboratory animals including chickens, mice, piglets, an

192 tract are described based on observations of laboratory animals including mice, rats and guinea-pigs,

193 ng humans and are absent in the skin of most laboratory animals including rodents, rabbits, and pigs.

194 rs including Alzheimer's disease (AD), while laboratory animals, including animal models of AD, can e

195 s in sleep quality are seen during ageing in laboratory animals, including the fruit fly Drosophila.

196 Evidence in laboratory animals indicates that exposure to stimulants

197 Extensive research with laboratory animals indicates that the hippocampus is cru

198 n a laboratory setting, and the infection of laboratory animals induces robust innate and adaptive im

199 In laboratory animals, intrasplenic hepatocyte transplantat

200 Prospective laboratory animal investigation.

201 risk activities were working with infectious laboratory animals involving significant aerosol exposur

202 Intravenous cocaine intake in laboratory animals is characterized by periods of appare

203 -grade veterinary product, the use of BSR in laboratory animals is not compliant with the Guide for t

204 HPVs, study of their natural transmission in laboratory animals is not possible.

205 measurement of specific-IgE antibody against laboratory animals is useful for understanding allergic

206 ccordance with the Guide for Care and Use of Laboratory Animals issued by the National Research Counc

207 ephalin increase splenic NK cell function in laboratory animals, it is anticipated that naltrexone tr

208 decreases the self-administration of COC in laboratory animals, it is proposed that the anti-addicti

209 spiratory and skin symptoms from exposure to laboratory animals (LA).

210 ften been neglected since most commonly used laboratory animals lack neuromelanin.

211 and the ethical need to minimise the use of laboratory animals, led us to develop tools to maximise

212 ilitating the primary female sex behavior in laboratory animals, lordosis behavior.

213 ssfully used to assess tinnitus in different laboratory animals, many of the finer details of this me

214 yeblink classical conditioning in humans and laboratory animals may be functionally similar.

215 The main types of tumour induced by SV40 in laboratory animals mirror the human cancers that have be

216 Epidemiological studies and laboratory animal model assays suggest that a high intak

217 Here, we describe a laboratory animal model for M. marinum disease in the le

218 To date, a laboratory animal model for the study of Sin Nombre viru

219 Epidemiological and laboratory animal model studies suggest that the effect

220 The lack of a standardized laboratory animal model that mimics key aspects of human

221 iatric patients, rhesus monkeys are an ideal laboratory animal model to investigate the maturation of

222 barrier (BBB), we performed cross-validating laboratory, animal model, and human brain tissue investi

223 Most existing laboratory animal models for urolithiasis rely on highly

224 Effective laboratory animal models of CML are needed to study the

225 Patients and laboratory animal models of temporal lobe epilepsy displ

226 an gastric function may differ from standard laboratory animal models.

227 oncogenic potential of this virus in several laboratory animal models.

228 ccines and evolved viruses for vaccines, and laboratory animal models.

229 o be good orally active antihypertensives in laboratory animal models.

230 the study of bacterial infection dynamics in laboratory animal models.

231 have been conducted with well-characterized laboratory animal models.

232 al of polyomavirus is primarily evaluated in laboratory animal models.

233 ed in the very young cartilage obtained from laboratory animals or in porcine and bovine articular ca

234 Although Pitx1 null mutations are lethal in laboratory animals, Pitx1 regulatory mutations show mole

235 Laboratory animals pretreated with antidepressants have

236 In plants and laboratory animals, QTL mapping is commonly performed us

237 cretion by releasing gastrin in a variety of laboratory animals, recent studies were unable to demons

238 atum, and increasing D(2) receptor levels in laboratory animals reduces alcohol consumption.

239 l differences in these responses are seen in laboratory animals, related in part to input from the pr

240 In laboratory animals, repeated administration of drugs of

241 izing spontaneous tumor development in aging laboratory animals represents an opportunity to advance

242 e possible source of conflicting findings in laboratory animal research are environmental differences

243 A tacit assumption in laboratory animal research is that animals housed within

244 ucibility is considered a serious problem in laboratory animal research, with important scientific, e

245 ), acute hepatitis E patients (n = 94), five laboratory animals (rhesus monkey, pig, New Zealand rabb

246 ode Caenorhabditis elegans, which block this laboratory animal's feeding.

247 zed rats with the ATLAS (Advanced Technology Laboratory Animal Scanner) small animal PET scanner deve

248 in the current Guide for the Care and Use of Laboratory Animals should be reconsidered.

249 Mice constitute ~70% of all the laboratory animal species used in biomedical research.

250 s enterohepatic disease in many domestic and laboratory animal species.

251 However, laboratory animal spinal cord injury cannot accurately m

252 Human clinical studies as well as laboratory animal studies demonstrate that offspring of

253 Laboratory animal studies have shown that parabens posse

254 Although laboratory animal studies have shown that the amygdala p

255 Laboratory animal studies of Pavlovian fear conditioning

256 Laboratory animal studies of substance P suggest a facil

257 literature from the last 40 years reporting laboratory animal studies pertaining to the persistent e

258 In a randomized, nonblinded laboratory animal study conducted between January 2013 a

259 In a randomized, nonblinded laboratory animal study, rats were randomized into a con

260 d as any model the deviates from the typical laboratory animals, such as mouse, rat, and worm.

261 s carried out using either human subjects or laboratory animals suggest that vitamin D and its analog

262 n establish conditioned place preferences in laboratory animals, suggest that these drugs activate bi

263 hese results are consistent with findings in laboratory animals, suggesting that differences in sexua

264 The observation of this phenomenon in older laboratory animals suggests that physiological changes p

265 denoviral vectors are typically performed in laboratory animals that lack immunity to adenovirus.

266 Handling can stimulate stress and anxiety in laboratory animals that negatively impacts welfare and i

267 dated using clinical samples from humans and laboratory animals that were known to be infected with p

268 ment of drug seeking is reliably observed in laboratory animals that were trained to self-administer

269 ism and blood pressure control of humans and laboratory animals, the focus is on human studies.

270 Of the commonly used laboratory animals, the rabbit is the only one in which

271 s of NMDA antagonist treatment in humans and laboratory animals, there is a fundamental lack of under

272 of the evidence at present is limited to the laboratory animals, this approach seems to hold a promis

273 Among laboratory animals, this tiny nematode is one of the sim

274 mulative neurotoxicity in exposed humans and laboratory animals through a direct inhibitory effect on

275 ing of core temperature during anesthesia in laboratory animals to avoid artifactual elevation of pro

276 raised concerns because it has been shown in laboratory animals to be neurotoxic to dopamine terminal

277 asma concentrations of anticancer drugs from laboratory animals to humans and among humans of differe

278 immunity by selective microbial exposure of laboratory animals to mimic that of humans.

279 e been shown to exacerbate the propensity of laboratory animals to spontaneously develop cardiodegene

280 AS and MP in 126 consecutive patients and 10 laboratory animals undergoing CMR.

281 smodium falciparum and in vivo infections of laboratory animals using rodent parasites.

282 that can reproduce these LC abnormalities in laboratory animals, we hypothesized that noradrenergic p

283 proach for screening an inbred population of laboratory animals, we identified two subpopulations of

284 time such an approach has been applied to a laboratory animal welfare problem.

285 Enhancing laboratory animal welfare, particularly in rodents, has

286 All procedures using laboratory animals were approved by the Institutional Ad

287 of Health guidelines for the care and use of laboratory animals were observed.

288 All procedures in which laboratory animals were used were approved by the instit

289 mune dysfunction, and increased infection in laboratory animals, whereas elemental diets, with or wit

290 reverse genetic and immunization studies of laboratory animals, which develop HCV-like chronicity.

291 urinary output, and renal histopathology in laboratory animals with acute renal dysfunction.

292 ch is protective against lethal challenge of laboratory animals with Coccidioides immitis, was fracti

293 ain reliable self-administration behavior by laboratory animals with delta-9-tetrahydrocannabinol (TH

294 contrast sexual differentiation in standard laboratory animals with differentiation in species exhib

295 yte transplantation improves the survival of laboratory animals with experimentally induced acute liv

296 establishes respiratory tract infections in laboratory animals with high efficiency.

297 On the basis of successful vaccination of laboratory animals with living irradiated, third-stage h

298 Vaccination of laboratory animals with recombinant Na-ASP-2 provides si

299 time course of onset of opiate dependence in laboratory animals, with the mathematical time course of

300 Further research on laboratory animals would be necessary to verify these ch